Antipsychotic News and Research RSS Feed - Antipsychotic News and Research

Antipsychotics are medicines used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as psychotherapy.
Coordinated specialty care more cost-effective for young people with first episode psychosis

Coordinated specialty care more cost-effective for young people with first episode psychosis

New analysis from a mental health care study shows that "coordinated specialty care" (CSC) for young people with first episode psychosis is more cost-effective than typical community care. Cost-effectiveness analysis in health care is a way to compare the costs and benefits of two or more treatment options. [More]
Add-on lamotrigine enhances bipolar depression treatment

Add-on lamotrigine enhances bipolar depression treatment

Combining lamotrigine with quetiapine improves the treatment of depressive symptoms in patients with bipolar disorder, with the benefits maintained for at least a year, show findings from the CEQUEL trial. [More]
Unhealthy microbiome shifts can lead to weight gain, obesity

Unhealthy microbiome shifts can lead to weight gain, obesity

The link between the gut microbiome and obesity seems clear, but just how changes to gut bacteria can cause weight gain is not. [More]
New drug therapies that target glutamate pathway may be effective for subgroups of patient with schizophrenia

New drug therapies that target glutamate pathway may be effective for subgroups of patient with schizophrenia

Mounting evidence indicates that disturbances in the brain's glutamate pathway contribute to symptoms of schizophrenia. Thus, the glutamate pathway has become the target of a number of new drug therapies. Findings published in the journal Biological Psychiatry suggest that at least one of these drugs may be an effective treatment for individuals in the early course of the illness. [More]
Mylan releases Clozapine Orally Disintegrating Tablets in U.S.

Mylan releases Clozapine Orally Disintegrating Tablets in U.S.

Mylan N.V. today announced the U.S. launch of Clozapine Orally Disintegrating Tablets, 25 mg and 100 mg, the generic version of Jazz Pharmaceutical's FazaClo. [More]
Atypical antipsychotic shows bipolar I depression efficacy

Atypical antipsychotic shows bipolar I depression efficacy

The atypical antipsychotic cariprazine may be effective for the treatment of bipolar I depression, phase II study findings show. [More]
Study explores diabetes screening for patients with severe mental illness

Study explores diabetes screening for patients with severe mental illness

A study just published in the Journal of the American Medical Association Internal Medicine examines diabetes screening for patients with severe mental illness, who are two to three times more likely to have type 2 diabetes than the general population. More than seven million Americans in the United States have severe mental illness, and there are many factors contributing to their increased risk of getting diabetes, including treatment with antipsychotic medication. [More]
New study compares effectiveness of clozapine with standard antipsychotics in adults with schizophrenia

New study compares effectiveness of clozapine with standard antipsychotics in adults with schizophrenia

In real-world settings, patients with schizophrenia whose symptoms do not respond to standard antipsychotic medications have better outcomes if they are switched to clozapine instead of another standard antipsychotic. They have fewer hospitalizations, stay on the new medication longer, and are less likely to need to use additional antipsychotics. [More]
Misleading symptoms confuse management of older patients with post-HSE relapse

Misleading symptoms confuse management of older patients with post-HSE relapse

Research shows that teenagers and adults with immune-mediated relapse after herpes simplex encephalitis rarely display the symptoms typically seen in children, delaying the initiation of vital immunotherapy. [More]
Team-based, coordinated specialty care approach produces better outcomes for people with first episode psychosis

Team-based, coordinated specialty care approach produces better outcomes for people with first episode psychosis

New research shows that treating people with first episode psychosis with a team-based, coordinated specialty care approach produces better clinical and functional outcomes than typical community care. Investigators also found that treatment is most effective for people who receive care soon after psychotic symptoms begin. [More]
Antipsychotic drugs more frequently used in Alzheimer's disease patients, new study finds

Antipsychotic drugs more frequently used in Alzheimer's disease patients, new study finds

Antipsychotic drugs are initiated in patients with Alzheimer's disease (AD) more frequently than in the general population - already 2-3 years before the Alzheimer's diagnosis, according to a new study from the University of Eastern Finland. [More]
Antipsychotics initiated frequently and used for long term in Alzheimer's patients

Antipsychotics initiated frequently and used for long term in Alzheimer's patients

Antipsychotic drugs are initiated in patients with Alzheimer's disease (AD) more frequently than in the general population – already 2–3 years before the Alzheimer's diagnosis, according to a new study from the University of Eastern Finland. Most commonly, antipsychotics were initiated during the six months following the Alzheimer's diagnosis; however, the incidence of new antipsychotic users was high also later on. The results were published in British Journal of Psychiatry. [More]
Lithium can be safe, effective for children suffering from bipolar disorder

Lithium can be safe, effective for children suffering from bipolar disorder

A multicenter study of young patients with bipolar disorder provides what may be the most scientifically rigorous demonstration to date that lithium -- a drug used successfully for decades to treat adults with the condition -- can also be safe and effective for children suffering from it. [More]
Aristada (aripiprazole lauroxil) extended release injection approved to treat adults with schizophrenia

Aristada (aripiprazole lauroxil) extended release injection approved to treat adults with schizophrenia

On October 5, the U.S. Food and Drug Administration approved Aristada (aripiprazole lauroxil) extended release injection to treat adults with schizophrenia. Aristada is administered by a health care professional every four to six weeks using an injection in the arm or buttocks. [More]
Study shows antipsychotic medication increases death risk in patients with Parkinson's disease psychosis

Study shows antipsychotic medication increases death risk in patients with Parkinson's disease psychosis

Antipsychotic drugs may increase the risk of death in people with Parkinson's disease psychosis (PDP), according to a new study led by researchers from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London. [More]
Mylan releases generic version of Invega in the U.S.

Mylan releases generic version of Invega in the U.S.

Mylan N.V. today announced the U.S. launch of Paliperidone Extended-Release Tablets 1.5 mg, 3 mg, 6 mg and 9 mg, the generic version of Janssen's Invega. [More]
Two-drug combination relieves depression in older adults

Two-drug combination relieves depression in older adults

More than half of older adults with clinical depression don't get better when treated with an antidepressant. But results from a multicenter clinical trial that included Washington University School of Medicine in St. Louis indicates that adding a second drug — an antipsychotic medication — to the treatment regimen helps many of those patients. [More]
ProPhase partners with Multi Health Systems to standardize electronic adaptations of PANSS

ProPhase partners with Multi Health Systems to standardize electronic adaptations of PANSS

ProPhase LLC, a global provider of applied measurement expertise, is announcing its partnership with Multi Health Systems, a Canadian publisher of psychological assessments and healthcare outcomes, to optimize and standardize electronic adaptations of the Positive and Negative Syndrome Scale (PANSS). [More]
Researchers examine neuroanatomical signature of schizophrenia in different ethnic groups

Researchers examine neuroanatomical signature of schizophrenia in different ethnic groups

While it is known that the incidence and outward symptoms of schizophrenia are strongly influenced by ethnic factors--for instance, patients from Asian ethnicities are more likely to experience visual hallucinations, whereas patients from western cultures and Caucasian ethnicities are more likely to suffer from auditory hallucinations--it was unclear if brain deficits would differ amongst suffers from various ethnic backgrounds. [More]
Special issue provides update on mental health diagnosis and treatment of older adults

Special issue provides update on mental health diagnosis and treatment of older adults

The aging of the population, shifting diagnostic criteria, and new health care policy initiatives are some of the factors driving changes in mental health treatment for older Americans, according to the September special issue of the Harvard Review of Psychiatry. The journal is published by Wolters Kluwer. [More]
Advertisement
Advertisement